Brookline Capital Management Forecasts UNCY FY2026 Earnings

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) – Stock analysts at Brookline Capital Management raised their FY2026 earnings estimates for shares of Unicycive Therapeutics in a research report issued to clients and investors on Wednesday, November 13th. Brookline Capital Management analyst K. Raja now forecasts that the company will post earnings of $1.88 per share for the year, up from their prior estimate of $1.85. The consensus estimate for Unicycive Therapeutics’ current full-year earnings is ($0.26) per share. Brookline Capital Management also issued estimates for Unicycive Therapeutics’ FY2027 earnings at $2.58 EPS and FY2028 earnings at $1.37 EPS.

Unicycive Therapeutics (NASDAQ:UNCY) last posted its quarterly earnings data on Wednesday, August 14th. The company reported ($0.15) EPS for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.08.

Several other brokerages have also issued reports on UNCY. Benchmark restated a “speculative buy” rating and set a $3.00 target price on shares of Unicycive Therapeutics in a research report on Friday, September 6th. HC Wainwright reiterated a “buy” rating and set a $2.50 price target on shares of Unicycive Therapeutics in a research note on Tuesday. Four equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $5.13.

Unicycive Therapeutics Stock Performance

Unicycive Therapeutics stock opened at $0.45 on Friday. Unicycive Therapeutics has a 52-week low of $0.20 and a 52-week high of $1.82. The business has a 50-day simple moving average of $0.43 and a two-hundred day simple moving average of $0.56.

Institutional Trading of Unicycive Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. Bleakley Financial Group LLC bought a new position in Unicycive Therapeutics in the 3rd quarter valued at $33,000. Virtu Financial LLC bought a new position in shares of Unicycive Therapeutics in the first quarter worth about $36,000. Acuta Capital Partners LLC bought a new position in shares of Unicycive Therapeutics in the third quarter worth about $807,000. Walleye Capital LLC purchased a new position in Unicycive Therapeutics in the 3rd quarter worth about $2,040,000. Finally, Great Point Partners LLC bought a new stake in Unicycive Therapeutics during the 3rd quarter valued at about $3,491,000. Institutional investors own 40.42% of the company’s stock.

About Unicycive Therapeutics

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.